Compare Enovix Corporation (ENVX) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Hims and Hers Health Inc — how do they compare? Enovix Corporation trades at $2.45 (market cap $549.72M), while Hims and Hers Health Inc trades at $30.88 (market cap $6.55B). The key difference: Hims and Hers Health Inc is far larger — about 11.9× Enovix Corporation's market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Hims and Hers Health Inc for 21 Days on average.
| ENVX | HIMS | |
|---|---|---|
Market Cap | $549.72M | $6.55B |
Volume | 6,635,687 | 14,842,814 |
Sector | Industrials | Health |
52-Week High | $13.19 | $62.76 |
52-Week Low | $2.50 | $14.52 |
Typical Hold Time | 11 Days | 21 Days |
Enterprise Value | $611.42M | $7.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.485, down 2.55% on the day, reflecting a bearish technical outlook. The company continues to post significant losses, with a net income margin of -473.89% in 2026, though quarterly earnings have consistently beaten expectations. Recent news is dominated by a sudden CEO transition, but the company reaffirmed its strategy and guidance, highlighting progress in its drone and defense battery supply chain.
The outlook is highly speculative. Analyst consensus is bullish with a $10.75 price target, but substantial execution risks and persistent cash burn pose a threat to shareholder value. Investment potential hinges on successful commercialization and achieving profitability, which remains distant.
Hims & Hers Health trades at $30.12, up 1.96% on the day, amid a bearish technical outlook and mixed fundamentals. The stock faces headwinds from a securities class action lawsuit related to an FTC complaint, with multiple law firms alerting investors ahead of a November 2, 2026 deadline. Financially, revenue grew to $2.35 billion in 2025, but net income turned negative in 2026, with a net loss of $142 million and a profit margin of -5.51%. Analyst consensus is a 'Hold' with a $32.17 price target, indicating limited upside from current levels.
The outlook for HIMS is cautious due to legal overhangs and profitability challenges. Investment opportunities hinge on resolving regulatory issues and returning to earnings growth, but risks include prolonged litigation, competitive pressures, and execution missteps. The stock's high valuation multiples, such as a P/E of 57.14, add vulnerability if growth disappoints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
